贝伐珠单抗联合CapeOx方案治疗晚期结直肠癌的Meta分析.docVIP

精品论文 参考文献 贝伐珠单抗联合CapeOx方案治疗晚期结直肠癌的Meta分析 项良光1,2 余海1 叶建新2（通讯作者） 　　【摘 要】 目的 评价贝伐珠单抗联合CapeOx化疗方案治疗晚期结直肠癌的临床疗效和不良反应。方法 检索PubMed、EMBASE、CENTRAL(Cochrane central register of controlled trials)、中国生物医学文献数据库(Chinese biomedical abstract database, CBM)和中国期刊全文数据库(China national knowledge infrastructure database, CNKI)和中国维普等数据库中关于贝伐珠单抗联合CapeOx方案治疗晚期结直肠癌的随机对照试验(randomized controlled trial, RCT)文献，检索时间从建库到2015年3月31日。然后对这些文献进行筛选和质量评价，用RevMan4.2软件对符合标准的文献进行Meta分析。结果 共纳入5项随机对照研究，共2459例晚期结直肠癌患者。合并后，OR=0.46(95% CI, 0.38～0.57)＞0。菱形完全位于垂直线的左侧。5篇文献中报道最多的是胃肠道功能紊乱、神经系统病变和手足综合症，其次还有粒细胞减少等，但联合治疗组的不良反应发生率比单纯化疗组没有显著增加。结论 贝伐珠单抗联合CapeOx方案化疗可以明显提高晚期结直肠癌患者的缓解率，而且不良反应发生率没有显著增加。 　　【关键词】 晚期结直肠癌； 贝伐珠单抗； CapeOx方案； 随机对照试验； Meta分析 　　A Meta-analysis of Bevacizumab Combined with CapeOx regimen Chemotherapy in Treatment of Advanced Colorectal Cancer. Xiang Liang-guang1,2, Yu Hai1, Ye Jian-xin2。 1. Department of General Surgery, Fuqing City Peoplersquo;s Hospital, Fujian Province Fuqing, 350030; 2. First Affiliated Hospital of Fujian Medical University, Fujian Province Fuzhou, 350005) 　　【Abstract】 Objective To evaluate the clinical efficacy and adverse events of bevacizumab combined with CapeOx regimen in treating advanced colorectal cancer. Methods Reviews from randomized controlled clinical trials (RCTs) of bevacizumab plus chemotherapeutic agents for patients with advanced colorectal cancer from the databases of Cochrane Library, Pubmed, EMBASE, CNKI, CBM and Wanfang Database for investigating side effects were retrieved. Then the methodological quality of included studies were evaluated. Meta-analysis was performed with the Review Manager 4.2. Results It was retrieved five out of 78 eligible papers encompassing 2 459 patients. After merging, OR=0.46(95% CI, 0.38~0.57)＞0. The rhombus located in the left of perpendicular line. The most common adverse events included gastrointestinal disorders, diarrhea, neurosensory toxicity and hand-foot syndrome, as well as granulocytopenia. However,